Mesothelioma Web logo



Onconase is a specialized enzyme found originally in frogs that speeds up the an enzyme that specializes in the break down of RNA which in turn can destroy a cell or stop it from dividing.

It is now being investigated as a possible treatment to certain cancers, including mesothelioma.

Par Phamaceuticals buys licensing rights for malignant mesothelioma drug Onconase from Alfacell

Alfacell Updates Status Of ONCONASE(R) Phase III Clinical Program

Protocol for the Onconase trial requires until 316 deaths have taken place before the statistical analysis can be done

Onconase Potential as Chemopreventive Agent in Mesothelioma

U.S. Orphan Drug Designation for Onconase for Treatment of Malignant Mesothelioma

ONCONASE Shows Survival Benefit in Patients with Malignant Mesothelioma

Encouraging Survival in Patients With Advanced Malignant Mesothelioma Treated With Alfacell's Onconase

Alfacell Provides Update on its Phase III Program of Onconase for The Treatment of Patients with Unresectable Malignant Mesothelioma

Onconase Clinical Trial Enrollment Expected to Be Ahead of Schedule

Alfacell Achieves Full Patient Enrollment Milestone for the ONCONASE Phase IIIb Registration Study in Unresectable Malignant Mesothelioma

Update on ONCONASE Phase IIIb Confirmatory Registration Trial; Releases First Interim Analysis Data

New Research Findings Published in National Academy of Sciences Journal Show Unique Promise of ONCONASE in the Prevention and Treatment of Mesothelioma and Lung Cancer Caused by Asbestos

Further Analysis of Phase III Data Using CALGB and EORTC Paradigms Reinforces Survival Benefits of ONCONASE(R) for the Treatment of Patients With Mesothelioma

U.S. Orphan Drug Designation for Onconase applied for

Researchers Identify Intracellular Pathway of Onconase


Note: Onconase is the brand name for ranpirnase.